STOCK TITAN
  1. Home
  2. Sec-filings
  3. PLSM
  4. [6-K] Pulsenmore Ltd. Current Report (Foreign Issuer)

Pulsenmore (PLSM) lands fresh AI funding for home ultrasound

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Pulsenmore Ltd. reported that the Israel Innovation Authority approved a $1.27 million grant for its SmartScan AI research and development program. Over the past month, total approved AI grants for Pulsenmore reached approximately $1.6 million, supporting two programs with a combined R&D scope of about $3.12 million.

The 12‑month SmartScan AI program aims to develop AI-powered, real-time guidance for home ultrasound, reducing dependence on user skill and enabling clinicians to handle a higher volume of remote examinations. Development will leverage data from more than 250,000 clinical scans and focus on fast, on-device processing using Edge AI.

Positive

  • Israel Innovation Authority approves a $1.27 million grant for Pulsenmore’s SmartScan AI program, providing non-equity funding for core R&D.
  • Total AI grants over the past month reach approximately $1.6 million, supporting two programs with a combined scope of about $3.12 million in AI-enabled home ultrasound development.

Negative

  • None.
SmartScan AI Grant Amount $1.27 million Grant approved by the Israel Innovation Authority for the SmartScan AI program
Total AI Grants in Past Month $1.6 million Approximate total AI grants approved for Pulsenmore over the past month
Combined Scope of AI Programs $3.12 million Combined development scope of the two AI programs supported by grants
Program Duration 12 months Planned duration of the SmartScan AI research and development program
Clinical Scans Dataset 250,000 scans Number of clinical scans on Pulsenmore’s platform to be used for development
home ultrasound medical
"a global leader in home ultrasound technology, today announced"
Edge AI technical
"optimization of advanced models for fast, on-device processing using Edge AI"
Edge AI refers to artificial intelligence systems that process data directly on local devices or nearby servers rather than sending information to distant data centers. This allows for faster decision-making and real-time responses, similar to how a home security camera can instantly detect motion without needing to connect to a remote server. For investors, edge AI represents a growing trend toward more efficient, responsive technology that can create new opportunities across various industries.
clinical workflow medical
"AI applications for clinical workflow efficiency"
Clinical workflow is the sequence of steps health professionals follow to diagnose, treat and document patient care, including how tasks, information and approvals move between staff and electronic records. Think of it like an assembly line or a recipe that ensures each step happens in the right order and on time. Investors care because smoother workflows reduce costs, speed revenue-generating services, improve compliance and make new medical technologies easier to adopt, affecting a provider's efficiency and profitability.
Israel Innovation Authority regulatory
"the Israel Innovation Authority has approved a grant"
ultrasound transducer medical
"combine position data from a new transducer and guide the user"

FAQ

What did Pulsenmore (PLSM) announce regarding new funding for its AI programs?
Pulsenmore announced that the Israel Innovation Authority approved a $1.27 million grant for its SmartScan AI program. This brings total AI grants over the past month to about $1.6 million, funding two R&D programs with a combined scope of roughly $3.12 million.

What is the objective of Pulsenmore’s SmartScan AI program mentioned in the 6-K?
SmartScan AI is a 12‑month R&D program to develop AI-powered real-time guidance for home ultrasound scans. It is designed to reduce operator dependence, improve image quality and consistency, and allow clinical teams to manage a greater volume of remote examinations efficiently.

How will Pulsenmore (PLSM) use data in developing SmartScan AI?
Pulsenmore plans to use data from more than 250,000 clinical ultrasound scans stored on its platform. This dataset will support optimizing advanced models for fast, on-device processing using Edge AI to guide image acquisition and enhance home ultrasound performance.

How many AI projects of Pulsenmore are supported by the Israel Innovation Authority?
Pulsenmore states that this is its second AI project to receive Israel Innovation Authority support within one month. Together, the two programs are backed by approximately $1.6 million in grants and have a combined development scope of around $3.12 million.

What women’s health applications will Pulsenmore’s SmartScan AI target?
SmartScan AI is intended to support three applications: fetal well-being and growth monitoring, ultrasound-based visual feedback on fetal head position and pushing efforts in advanced pregnancy, and monitoring follicles and endometrial thickness during fertility treatment in home-based ultrasound settings.

How does the new AI grant align with Pulsenmore’s broader AI strategy?
The new grant complements a July 2026 program focused on clinical workflow AI, together covering home ultrasound acquisition and workflow efficiency. Pulsenmore aims for its platform to support a growing volume of home examinations efficiently and at scale using integrated AI capabilities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of August 2026

 

001-43033

(Commission File Number)

 

PULSENMORE LTD.

(Exact name of Registrant as specified in its charter)

 

8 Omarim St.

Omer 8496500, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

 

On August 17, 2026, Pulsenmore Ltd. issued a press release entitled “Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program”. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
     
99.1   Press Release, dated August 17, 2026.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Pulsenmore Ltd.
     
Date: August 17, 2026 By: /s/ Eran Hirsh
    Eran Hirsh
    Chief Financial Officer

 

 

 

 

 

Exhibit 99.1

 

Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program

 

The new grant brings the total AI grants approved for Pulsenmore over the past month to approximately $1.6 million, supporting two programs with a combined scope of approximately $3.12 million.

 

The program is designed to advance the next generation of home ultrasound through AI-powered real-time ultrasound analysis and dynamic guidance of the image acquisition process, with the goal of improving scan quality and consistency and enabling home ultrasound to be deployed at greater scale.

 

Ramat Gan, Israel, August 17, 2026 – Pulsenmore Ltd. (NASDAQ, TASE: PLSM), a global leader in home ultrasound technology, today announced that the Israel Innovation Authority has approved a grant of $1.27 million for the Company’s SmartScan AI research and development program. The 12-month program is intended to develop technology combining artificial intelligence, and real-time feedback to independently guide pregnant women while performing ultrasound scans at home.

 

This is Pulsenmore’s second AI project to receive support from the Israel Innovation Authority within one month, further advancing the Company’s strategy to develop the next generation of home ultrasound.

 

SmartScan AI is designed to address one of the key challenges in ultrasound, the dependence on user skill to acquire high-quality images. The planned system will combine position data from a new transducer and guide the user until a suitable image is obtained. The goal is to reduce operator dependency and enable clinical teams to support a greater volume of remote examinations. Development is expected to draw on data from more than 250,000 clinical scans accumulated on the Company’s platform and include the optimization of advanced models for fast, on-device processing using Edge AI.

 

Dr. Elazar Sonnenschein, Founder and CEO of Pulsenmore, commented: “Receiving a second grant for an AI program within one month represents another vote of confidence in our technology and the Company’s strategic direction. We are building an AI layer that will operate across the process, from ultrasound image acquisition through the clinical workflow. Our goal is to enable our platform to support a significantly greater number of home examinations without requiring a corresponding increase in clinical resources. We believe this is one of the keys to making home ultrasound a more significant part of pregnancy monitoring and fertility care.”

 

SmartScan AI is intended to support three applications in women’s health: fetal well-being and growth monitoring; the use of ultrasound in advanced pregnancy to provide women with visual feedback on fetal head position and the effect of their pushing efforts as part of preparation for delivery; and monitoring of follicles and endometrial thickness during fertility treatment.

 

The new grant follows Pulsenmore’s selection in July 2026 for a joint Israel Innovation Authority and Ministry of Health program focused on the development and clinical validation of AI applications for clinical workflow efficiency. Together, the two programs advance complementary elements of Pulsenmore’s AI strategy, applying AI across both home ultrasound acquisition and the clinical workflow, with the goal of enabling the Company’s home ultrasound platform to support a growing volume of examinations efficiently and at scale.

 

 

 

 

About Pulsenmore

 

Pulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes prenatal care patient-centric, expanding access and improving continuity of care. For more information, visit www.pulsenmore.com

 

This press release contains forward-looking statements. In particular, statements using words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “contemplate,” “do not believe,” “aim,” “goal,” “due,” “predict,” “plan,” “project,” “continue,” “potential,” “positioned,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to the expected development, timing, performance, validation, regulatory pathway and commercial potential of the SmartScan AI program, and the use of the grant. Forward-looking statements reflect Pulsenmore’s current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company’s Annual Report on Form 20-F, filed with the SEC on March 30, 2026. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.

 

Investor Contact:

 

Miri Segal-Scharia

MS-IR LLC

msegal@ms-ir.com

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases